As the name implies, Concierge MedTravel is a medical travel service. Concierge arranges appointments, international travel, transportation, hotel and hospital accommodations for clients. The company caters to men in need of a minimally invasive prostate cancer treatment, specifically an alternative prostate cancer treatment known as Ablatherm High Intensity Focused Ultrasound (HIFU) that is not available in the U.S. Concierge sends customers to St. Josef Hospital, a medical center with a team of 20 urological medical specialists, located at the University of Regensburg in Germany. Concierge will coordinate with your local physician, who will continue to provide care once treatment is…
Browsing: Video
ImmunoVaccine Technologies (IVT) is a private biotechnology company developing therapeutic cancer and infectious disease vaccines. VacciMax technology is based on a novel approach to the use of liposomes. While liposomes typically contribute only marginally to the production of an immune response, IVT has discovered that liposomes stabilized by VacciMax technology significantly enhance antibody production. The company believes VacciMax will have the greatest impact in therapeutic cancer applications by stimulating earlier, more powerful, and longer lasting immune responses. An End to Three Dose Vaccine Regimens? In a variety of human infectious disease and cancer models, a three dose regime of vaccine…
Each year over 234,000 new cases of prostate cancer are diagnosed in the U.S. Treatment options include surgery, radiation therapy, hormone therapy, “watchful waiting” and cryotherapy. Treatment depends on factors including the patient’s age, the stage of the cancer and the presence of other pre-existing medical conditions. To date, radical prostatectomy has been the preferred treatment – surgically removing the cancerous tissue carries a high success rate, but is often associated with unwanted side effects such as impotence and incontinence. Radiation therapy, which includes traditional external radiation and interstitial radioactive seed therapies (brachytherapy), is used to treat the early-stage disease.…
Clarient provides access to technologies and services for the characterization, assessment and treatment of cancer. The company offers a full range of diagnostic technologies and services for the clinical cancer diagnostics industry including immunohistochemistry, flow cytometry, in-house molecular testing, complete tumor work-up and consultation services to follow-up and monitor disease after diagnosis. Client services include: diagnosing solid tumors, cancer sub-typing, classifying patients into prognostic categories (i.e. low, medium and high risk groups), identifying which drugs or therapy paths are best for patients, monitoring patient on therapy, searching for residual disease during and post therapy, and detecting relapse or cancer transformation.…
Early detection of ischemic injury, though difficult to achieve, is becoming increasingly critical to the proper utilization of new interventional procedures. Experts note that although Magnetic Resonance Angiography can evaluate vessel anatomy and patency, the method cannot characterize tissue viability. Rockland Technimed’s Tissue Viability Imaging Agent is able to assess the quality and function of the underlying tissue; it can differentiate reversible or irreversible tissue injury. Rockland’s technology is based on the normal process of cellular regeneration of adenosine triphosphate with concomitant conversion of oxygen to water. The company’s Oxy-17 is formulated using a stable, non-radioactive isotope of Oxygen that…
Irvine, California-based NeoMatrix offers the HALO Breast Pap Test, a fully automated, noninvasive breast disease screening device designed for use in a primary care setting. HALO is FDA approved for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid is used to determine and/or differentiate normal, pre-malignant and malignant cells. If made a part of routine check-ups, NeoMatrix believes HALO would enable physicians and patients to monitor cellular changes within breast ducts earlier, before they develop into larger, potentially cancerous lesions discovered by via conventional breast cancer screening modalities like mammography or manual breast examination. Over 40,000…
We gathered this footage back in September at the Think Equity G5 Growth Conference. In this segment, Gulfo discusses MelaFind – a handheld device that capture images of suspicious pigmented skin lesions. The data is then analyzed against a database of melanomas and benign lesions. The “Lesion Classifier” recommends whether the lesion should be biopsied. With assistance provided by MelaFind, physicians could diagnose more melanomas at the earliest curable stage, reducing both treatment costs and the number of unnecessary biopsies. Gulfo describes MelaFind as “better, cheaper medicine.” Electro-Optical Sciences (EOS) initiated a clinical trial back in January and anticipates submitting…